

# Newborn Screening Quality Assurance Program

## PROFICIENCY TESTING PROGRAM FOR ANTI-HIV-1 IN DRIED BLOOD SPOTS

Quarterly Report

Quarter 4

November 2012

### INTRODUCTION

The Anti-HIV-1 proficiency testing (PT) panel for Quarter 4, 2012, consisted of five individual-matrix dried-blood spot (DBS) specimens representing a variety of serostatuses. HIV antibody screening and confirmatory tests should identify all HIV-positive specimens, regardless of subtype. Method and laboratory performance are evaluated by challenging participants with specimens representing HIV-negative and positive serostatuses.

On October 9, 2012, we sent the Quarter 4 Anti-HIV-1 panel to 15 domestic and 13 international participants. We received data reports from 25 of the 28 participating laboratories by the designated deadline date. This report is the outcome of data reported for the Quarter 4, 2012, Anti-HIV-1 PT specimens. There were no misclassifications reported. This quarterly report is distributed to all participants and to program colleagues upon request.

Each participant was asked to analyze the specimens for anti-HIV-1 with the assay schemes they routinely use and to report for each specimen the screening results along with results from any confirmatory assays performed for presumptive positives. A final inter-

pretation for each specimen must be submitted to receive a grade.

### PARTICIPANTS' RESULTS

Table 1 shows the overall frequency of reported reactive, non-reactive, and indeterminate screening results for specimens 41241-41245.

In Part 1 of the report, Table 2 shows the number of laboratories using each screening method/kit both for the primary and secondary screens.

Table 3 shows the summary of screening errors by method. There were no false negative or false positive errors this quarter.

In Part 2 of the report, Table 4 shows the number of laboratories using each confirmatory method/kit.

Table 5 shows the Reported Frequency of Bands by Western Blot for each of the PT specimens that tested positive for the Anti-HIV-1 screening analysis.

The Quality Assurance Program will ship next quarter's HIV-1 DBS proficiency testing specimens on January 14, 2013. ❖

### CONFERENCES AND MEETINGS

2012 HIV Diagnostics Conference December 12-14, 2012 at the Sheraton Hotel in downtown Atlanta, Georgia. [www.hivtestingconference.org](http://www.hivtestingconference.org) ❖

### SPOTLIGHT

In 2012, CDC issued a new health department funding opportunity announcement (FOA) that is designed to increase the impact of HIV prevention. This program will distribute \$359 million annually to support HIV testing and other prevention efforts and using a High Impact Prevention approach. Of these funds, \$54.8 million goes to support CDC's Expanded Testing Program that is being conducted in 34 high-prevalence areas with 90% of the country's AIDS epidemic. This program supports health departments in working with hospitals and health care providers to conduct routine opt-out testing and provide targeted HIV testing in community-based settings. The project focuses on HIV testing among African Americans, Latinos, MSM and IDUs and emphasizes linking those who test positive to medical care.

<http://www.cdc.gov/hiv/resources/factsheets/PDF/LHI-Factsheet-FINAL-6-26-12.pdf>



Direct inquiries to:  
Centers for Disease Control and Prevention (CDC)  
4770 Buford Highway, NE, MS/F43  
Atlanta, GA 30341-3724

Quarterly publications for colleagues and participants of the Proficiency Testing Program for Anti-HIV-1 in Dried Blood Spots.

Phone: 770-488-7897  
FAX: 770-488-4255  
E-mail: [NMeredit@cdc.gov](mailto:NMeredit@cdc.gov)

Editor: Nancy Meredith  
Production: Connie Singleton



**Anti-HIV-1 PT Report  
Quarter 4, 2012**

**TABLE 1: Frequency Distribution: Outcome of Final Interpretations (25 Labs)**

<b>Specimen Number</b>	<b>Expected Results</b>	<b>Non- Reactive</b>	<b>Reactive</b>	<b>Indeterminate</b>	<b>Not Reported</b>
41241	Non-Reactive	25	0	0	3
41242	Non-Reactive	25	0	0	3
41243	Reactive	0	25	0	3
41244	Non-Reactive	25	0	0	3
41245	Non-Reactive	25	0	0	3

**Part 1. SCREENING**

**TABLE 2: Number of Screening Methods Reported; Includes Primary and Secondary Methods**

<b>Method Code</b>	<b>Kit Source</b>	<b>Participants</b>
10	Fujirebio Serodia-HIV 1,2	2
11	In House	2
12	Other	4
27	Tecnosuma (Cuba) UMELISA HIV 1+2	2
40	Avioq HIV-1 Microeleisa Systems	12
41	Bio-Rad HIV-1/Hiv-2 plus O EIA	1
	<b>Total</b>	<b>23*</b>

\*Note: Two laboratories did not report EIA data and reported final interpretations based on a Western Blot confirmatory tests.



This **NEWBORN SCREENING QUALITY ASSURANCE PROGRAM** report is an internal publication distributed to program participants and selected program colleagues. The laboratory quality assurance program is a project cosponsored by the **Centers for Disease Control and Prevention (CDC)** and the **Association of Public Health Laboratories**.

**CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC)**  
**ATLANTA, GA 30341**

**Director**

Thomas R. Frieden, M.D., M.P.H.

**Director**

**National Center for Environmental Health**

Christopher J. Portier, Ph.D.

**Director**

**Division of Laboratory Sciences**

James L. Pirkle, M.D., Ph.D.

**Chief**

**Newborn Screening and Molecular Biology Branch**

Carla Cuthbert, Ph.D.



**Contributors:** Barbara W. Adam  
Carol Bell  
Dana Chafin  
Paul Dantonio  
Victor R. De Jesus, Ph.D.  
Marie C. Earley, Ph.D.  
Sharon Flores  
Elizabeth M. Hall  
Christopher Haynes, Ph.D.  
Kevin Lanza  
Francis Lee, Ph.D.  
Lixia Li, Ph.D.  
Timothy Lim, Ph.D.  
Daniel Mandel, Ph.D.  
Joanne Mei, Ph.D.  
Nancy Meredith  
Tracey Myers  
Kelsey Sheard  
Jennifer Taylor, Ph.D.  
Robert Vogt, Ph.D.  
Irene Williams  
Golriz Yazdanpanah  
Hui Zhou, Ph.D.  
Sherri Zobel

**Production:** Sarah Brown  
Felicia Manning  
Teresa Moore  
Connie Singleton



**ASSOCIATION OF PUBLIC HEALTH LABORATORIES**  
**SILVER SPRING, MD 20910**

**President**

Charles Brokopp, Dr. P.H., M.P.H.

**Chairman, Newborn Screening and Genetics in Public Health Committee**

Susan M. Tanksley, Ph.D.

**Chairman, Newborn Screening Quality Assurance Quality Control Subcommittee**

Patrick Hopkin, B.S.

**INQUIRIES TO:**

*Nancy Meredith, Editor • Centers for Disease Control and Prevention (CDC)*  
*Newborn Screening Quality Assurance Program • Mailstop F-43*  
*4770 Buford Highway, N.E. • Atlanta, GA 30341-3724*  
*Phone (770) 488-4582 • FAX (770) 488-4255 • E-mail: NMeredith@cdc.gov*